High-throughput fluorescence polarization method for identification of FKBP12 ligands.
FKBP12 is best known as the target of the widely used immunosuppressive drug FK506 but may also play a role in neuronal survival. Nonimmunosuppressive ligands of FKBP12 have been shown to have neuroprotective and neuroregenerative activity both in vitro and in vivo, stimulating interest in the development of high-throughput screens to rapidly identify novel ligands. FKBP12 was expressed as a His(6)-fusion in bacteria and purified by metal ion affinity and gel filtration chromatography. A high-throughput fluorescence polarization assay was developed to identify novel ligands of FKBP12. Dissociation constant values of known FKBP12 ligands measured by the new method agreed closely with K(i) values obtained by assaying inhibition of the rotamase activity of the enzyme. The fluorescence polarization assay is rapid, robust, and inexpensive and does not generate radioactive waste. It is very well suited for high-throughput screening efforts.
Department of Neuroscience, Pharmaceutical Research Institute, Bristol-Myers Squibb, Inc., Wallingford, CT, USA.
S
S
Bollini
J J
JJ
Herbst
G T
GT
Gaughan
T A
TA
Verdoorn
J
J
Ditta
G M
GM
Dubowchik
A
A
Vinitsky
D004353:Drug Evaluation, Preclinical / Q000379:methods; D005454:Fluorescence Polarization / Q000379:methods*; D006639:Histidine / Q000235:genetics; D006801:Humans; D008024:Ligands; D011994:Recombinant Proteins / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D015203:Reproducibility of Results; D022061:Tacrolimus Binding Protein 1A / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*
D008024:Ligands; D011994:Recombinant Proteins; D006639:Histidine; D022061:Tacrolimus Binding Protein 1A